Danish drug manufacturer Novo Nordisk generated over 108 billion kroner – or some 85 percent of its total sales – in the diabetes and obesity care segment. The biopharm segment was significantly lower, generating some 19 billion kroner of the company’s total sales.
…. more: Statista.com (Quelle/Source)